Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 10-K | Annual report filed with the U.S. Securities and Exchange Commission |
| 10-Q | Quarterly report filed with the U.S. Securities and Exchange Commission |
| 25-OH | 25-hydroxy (vitamin D) |
| AAC | Augmentative and alternative communication |
| AAV | Adeno-associated virus |
| AAV2 | Adeno-associated virus serotype 2 |
| AAV9 | Adeno-associated virus serotype 9 |
| aBMD | Areal bone mineral density |
| AE | Adverse event |
| AED | Antiepileptic drug |
| AHFS | American Hospital Formulary Service |
| ARSD | Australian Rett Syndrome Database |
| AUD | Australian dollars |
| BDNF | Brain-derived neurotrophic factor |
| BIA | Budget impact analysis |
| BID | Twice daily |
| BiPAP | Bilevel positive airway pressure |
| BLA | Biologics License Application |
| BMC | Bone mineral content |
| BMD | Bone mineral density |
| BMI | Body mass index |
| BSC | Best supportive care |
| CAD | Canadian dollars |
| CarerQol-7D | Care-related Quality of Life instrument, seven dimensions |
| CBD | Cannabidiol |
| CDA-AMC | Canada's Drug Agency (L'Agence des médicaments du Canada) |
| CDKL5 | Cyclin-dependent kinase-like 5 |
| CGI | Clinical Global Impression |
| CGI-I | Clinical Global Impression-Improvement |
| CGI-S | Clinical Global Impression-Severity |
| CHQ-PF50 | Child Health Questionnaire Parent Form 50 |
| CHU | Centre hospitalier universitaire (university hospital centre) |
| CI | Confidence interval |
| CMC | Chemistry, manufacturing, and controls |
| CNS | Central nervous system |
| CNV | Copy number variant |
| COA | Clinical outcome assessment |
| COE | Center of excellence |
| CPT | Current Procedural Terminology |
| CRO | Caregiver-reported outcome |
| CSF | Cerebrospinal fluid |
| CTA | Clinical trial application |
| DCE | Discrete choice experiment |
| DEXA | Dual-energy X-ray absorptiometry |
| DIMS | Disorders of initiating and maintaining sleep |
| DLT | Dose-limiting toxicity |
| DM | Developmental milestone |
| DMA | Developmental Milestones Assessment |
| DMPA | Depot medroxyprogesterone acetate |
| DNA | Deoxyribonucleic acid |
| DNMT3 | DNA methyltransferase 3 |
| DRG | Dorsal root ganglion |
| DTC | Delayed treatment cohort |
| DXA | Dual-energy X-ray absorptiometry |
| ECG | Electrocardiogram |
| ED | Emergency department |
| EKG | Electrocardiogram |
| EMA | European Medicines Agency |
| EPAR | European public assessment report |
| EQ-5D-5L | EuroQol 5-dimension, 5-level questionnaire |
| EU | European Union |
| FDA | U.S. Food and Drug Administration |
| FL-MeCP2 | Full-length methyl-CpG-binding protein 2 |
| FOXG1 | Forkhead box G1 |
| FTD | Fast Track designation |
| GABA | Gamma-aminobutyric acid |
| GERD | Gastroesophageal reflux disease |
| GFAP | Glial fibrillary acidic protein |
| GFP | Green fluorescent protein |
| GI | Gastrointestinal |
| GMP | Good manufacturing practice |
| GTC | Generalized tonic-clonic |
| H2 | Histamine-2 (receptor) |
| HCP | Healthcare professional |
| HCRU | Healthcare resource utilization |
| HR | Hazard ratio |
| HRU | Healthcare resource utilization |
| HS | Hand stereotypies |
| I2 | I-squared statistic of heterogeneity |
| ICER | Incremental cost-effectiveness ratio |
| ICH | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use |
| ICM | Intracisterna magna |
| ICV | Intracerebroventricular |
| IDMC | Independent Data Monitoring Committee |
| ILAP | Innovative Licensing and Access Pathway |
| IND | Investigational New Drug application |
| INN | International Nonproprietary Name |
| IQR | Interquartile range |
| IRSF | International Rett Syndrome Foundation |
| ISCD | International Society for Clinical Densitometry |
| IT | Intrathecal |
| ITC | Immediate treatment cohort |
| ITR | Inverted terminal repeat |
| IU | International units |
| JNDA | Japanese New Drug Application |
| KO | Knockout |
| LP | Lumbar puncture |
| LRTI | Lower respiratory tract infection |
| LS | Least squares |
| LSM | Least squares mean |
| MAA | Marketing authorization application |
| MAD | Maximum administered dose |
| MBA | Motor Behavior Assessment |
| MBD | Methyl-CpG-binding domain |
| MCGR | Magnetically controlled growing rods |
| MCS | Mental component score |
| MCSF | Monthly countable seizure frequency |
| MDS | MECP2 duplication syndrome |
| MeCP2 | Methyl-CpG-binding protein 2 |
| MECP2 | Methyl-CpG-binding protein 2 gene |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MIM | Mendelian Inheritance in Man |
| miRARE | MicroRNA-responsive autoregulatory element |
| miRNA | MicroRNA |
| MLPA | Multiplex ligation-dependent probe amplification |
| mRNA | Messenger ribonucleic acid |
| MSEL-A | Mullen Scales of Early Learning, adapted |
| MTD | Maximum tolerated dose |
| NCoR | Nuclear receptor corepressor |
| NCV | Nerve conduction velocity |
| NfL | Neurofilament light chain |
| NGS | Next-generation sequencing |
| NHP | Nonhuman primate |
| NHS | Natural History Study; National Health Service |
| NID | NCoR/SMRT interaction domain |
| NIH | National Institutes of Health |
| NINDS | National Institute of Neurological Disorders and Stroke |
| NMS | Neuromuscular scoliosis |
| NOL | No Objection Letter |
| OP | Outpatient |
| ORCA | Observer-Reported Communication Ability |
| OT | Occupational therapy |
| PABAK | Prevalence-adjusted bias-adjusted kappa |
| PCR | Polymerase chain reaction |
| PCS | Physical component score |
| PedsQL | Pediatric Quality of Life Inventory |
| PEP | Positive expiratory pressure |
| PGI-I | Parental Global Impressions-Improvement |
| PPPY | Per patient per year |
| PPQ | Process performance qualification |
| PRV | Priority review voucher |
| PSF | Posterior spinal fusion |
| PT | Physical therapy |
| QALY | Quality-adjusted life-year |
| QoL | Quality of life |
| QTc | Corrected QT interval |
| R-MBA | Revised Motor Behavior Assessment |
| rAAV9 | Recombinant adeno-associated virus serotype 9 |
| RAS | Rett syndrome-associated scoliosis |
| RDH1 | Replication dependent histone 1 |
| REM | Rapid eye movement |
| REMS | Risk Evaluation and Mitigation Strategy |
| RF | Respiratory failure |
| RMAT | Regenerative Medicine Advanced Therapy |
| RNA | Ribonucleic acid |
| RNHS | Rett Natural History Study |
| RoA | Route of administration |
| RS-DMA | Rett Syndrome Developmental Milestone Assessment |
| RSBQ | Rett Syndrome Behaviour Questionnaire |
| RSGMS | Rett Syndrome Gross Motor Scale |
| RTT | Rett syndrome |
| SAE | Serious adverse event |
| SAP | Statistical analysis plan |
| scAAV9 | Self-complementary adeno-associated virus serotype 9 |
| SD | Standard deviation |
| SE | Standard error |
| SEC | U.S. Securities and Exchange Commission |
| SF-36v2 | 36-Item Short Form Health Survey, version 2 |
| SLR | Systematic literature review |
| SMRT | Silencing mediator of retinoic acid and thyroid hormone receptor |
| ssAAV9 | Single-stranded adeno-associated virus serotype 9 |
| SSRI | Selective serotonin reuptake inhibitor |
| ST | Speech therapy |
| TEAE | Treatment-emergent adverse event |
| TM | Tamoxifen |
| TRD | Transcriptional repression domain |
| TROF | Trofinetide |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| UNII | Unique Ingredient Identifier |
| US | United States |
| USAN | United States Adopted Name |
| USD | U.S. dollars |
| UTR | Untranslated region |
| vg | Vector genomes |
| WHO | World Health Organization |
| WT | Wild type |
| XCI | X-chromosome inactivation |
| YOA | Years of age |
| ZA | Zoledronic acid |